Vanda Pharmaceuticals (VNDA) Stock Price, Quote, News & History | Benzinga

SPY773.10+0.00%QQQ724.80−0.06%BTC/USD84,699.99+2.12%DIA528.03+0.06%GLD379.41+0.12%TLT80.30+0.07%

Vanda Pharmaceuticals Inc (VNDA) Stock Price, Quote, News & History

VNDANASDAQ

Trade with Public

Trade with Public

$4.01

-0.16-3.84%

Last update: Oct 21, 4:05 PM

$4.05

-0.12-2.88%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$4.18

Close

$4.01

Volume / Avg.

1.09M / 964.39K

Day Range

$3.97 - $4.18

52 Wk Range

4.00 - 9.94

Market Cap

$243.55M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

21

Short Interest

13.67%

Days to Cover

6.45

Recent Vanda Pharmaceuticals Inc News

Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint

Vanda Pharmaceuticals announced its Phase 3 trial for VQW-765 failed to meet primary endpoints for treating acute social anxiety disorder.

Vandana Singh

Vanda Eyes First FDA-Approved Delayed Sleep-Wake Disorder Drug

Vanda's Phase 3 trial of HETLIOZ for DSWPD met its primary endpoint, advancing sleep onset by 42.5 minutes. sNDA submission planned.

Vandana Singh

This Equinix Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Top Wall Street analysts changed outlook on top names. See analyst ratings page for full view. EQIX stock initiated with Outperform rating.

Avi Kapoor

Vanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin Drug

Vanda stock climbs after the FDA approves Bysanti for bipolar disorder and schizophrenia and reviews rare skin disease treatment.

Vandana Singh

What's Going On With Vanda Pharma Stock Tuesday?

FDA's approval of Bysanti boosts Vanda's portfolio, with potential to treat bipolar disorder, schizophrenia, and major depressive disorder.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-142.33M

Investing Cash Flow (TTM)

120.27M

Financing Cash Flow (TTM)

-2.79M

Free Cash Flow (TTM)

-153.01M

Capital Expenditure (TTM)

-10.67M

Net Change in Cash (TTM)

-24.85M

Analyst Trends and Forecast

1

May

2

Aug

1

Sep

1

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$105.23M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

1.15

PB Ratio (TTM)

1.15

Earnings Yield % (TTM)

-111.14%

Earnings Yield % (FWD)

-19.28%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$3.64

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$2.79M

Total Cash

$55.88M

Debt to Equity

0.10

Issuance of Debt (TTM)

-$2.79M

Repayment of Debt (TTM)

-$2.79M